Identification of subjects at the early stages of Alzheimer's disease (AD) is fundamental for
drug development and possible intervention or prevention of cognitive decline. The concept …

Alzheimer's disease (AD) is the most common form of dementia. The development of assay
technologies able to diagnose early-stage AD is important. Blood tests to detect biomarkers …

An increasing population of dementia patients produces substantial societal impacts. We
assessed the prevalence of mild cognitive impairment (MCI) and all-cause dementia …

BACKGROUND/PURPOSE: Behavioral and psychologic symptoms of dementia (BPSD) are
major sources of a caregiver's burden and also the most important factor when considering …

Objective To examine whether plasma neurofilament light chain (NfL) levels were
associated with motor and cognitive progression in Parkinson disease (PD). Methods This …

Neurofibrillary tangles are associated with cognitive dysfunction, and hippocampal atrophy
with increased CSF tau markers. However, the plasma tau levels of Alzheimer's disease …

Objective α-Synuclein is critical to the pathogenesis of Parkinson's disease (PD). Few
studies examined the plasma levels of α-synuclein due to the exceptionally low level of α …

Conventional model-based or statistical analysis methods for functional MRI (fMRI) suffer
from the limitation of the assumed paradigm and biased results. Temporal clustering …

A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several
biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include …

The 42 amino acid form of amyloid-ß (Aß42) plays a key role in the pathogenesis of
Alzheimer's disease (AD) and is a core biomarker for the diagnosis of AD. Numerous studies …